Literature DB >> 29870918

The prevalence and function of CD4+CXCR5+Foxp3+ follicular regulatory T cells in diffuse large B cell lymphoma.

Zhanshan Cha1, Haihui Gu1, Yan Zang1, Zi Wang1, Jinqi Li1, Weihua Huang1, Aihua Qin1, Lishuang Zhu1, Xiaohua Tu1, Ning Cheng1, Haihan Song2, Baohua Qian3.   

Abstract

CD4+CXCR5+Foxp3+ follicular regulatory T (Tfr) cells possess critical roles in suppressing the germinal center reaction, B cell activation, and follicular helper T cell (Tfh) cytokine secretion. Since diffuse large B cell lymphoma (DLBCL) can arise from B cells undergoing germinal center reaction and/or differentiation, we hypothesized that Tfr cells might be involved in DLBCL. In the present study, we recruited thirty-five DLBCL patients and twenty-five healthy controls. Data showed that DLBCL patients presented an enrichment of circulating CD4+CXCR5+Foxp3+ Tfr cells compared to controls. In the primary tumor isolated from enlarged lymph nodes, Tfr cells made up of roughly 3% to 16% of infiltrating T cells. Higher levels of tumor-infiltrating Tfr cells were observed in patients with less advanced DLBCL stages, and in patients that stayed in remission 24 months after the initial R-CHOP treatment. High BCL6 and high FOXP3 expression was observed in Tfr cells ex vivo. After anti-CD3/CD28 and IL-2 stimulation, the Tfr cells more closely resembled Treg cells and presented high IL10 and TGFB1 expression. CD4+CD25+CXCR5+ Tfr cells and CD4+CD25+CXCR5- non-Tfr Treg cells could suppress CD4+CD25- Tconv cell and CD8+ T cell proliferation with similar capacity. However, Tfr cells were less capable of suppressing IFNG expression than Treg cells, and although both cell types supported CD19+ tumor cell proliferation, Tfr cells were less supportive than the non-Tfr Treg cells. Overall, this study suggested that Tfr cells were involved in intratumoral immunity, were likely beneficial to DLBCL patients, and were functionally distinctive from non-Tfr Treg cells. The distribution pattern and the prognostic value of Tfr cells in DLBCL should be examined in further studies.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Diffuse large B cell lymphoma; Follicular helper T cell; Follicular regulatory T cell

Mesh:

Substances:

Year:  2018        PMID: 29870918     DOI: 10.1016/j.intimp.2018.05.025

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  8 in total

1.  CXCL13 Signaling in the Tumor Microenvironment.

Authors:  Muzammal Hussain; Jinsong Liu; Gui-Zhen Wang; Guang-Biao Zhou
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Lineage Reprogramming of Effector Regulatory T Cells in Cancer.

Authors:  Michael L Dixon; Jonathan D Leavenworth; Jianmei W Leavenworth
Journal:  Front Immunol       Date:  2021-07-28       Impact factor: 7.561

3.  Remodeling of the tumor microenvironment via disrupting Blimp1+ effector Treg activity augments response to anti-PD-1 blockade.

Authors:  Michael L Dixon; Lin Luo; Sadashib Ghosh; Jeffrey M Grimes; Jonathan D Leavenworth; Jianmei W Leavenworth
Journal:  Mol Cancer       Date:  2021-11-20       Impact factor: 27.401

4.  The characteristics and novel clinical implications of CD4+CXCR5+Foxp3+ follicular regulatory T cells in breast cancer.

Authors:  Xianyuan Miao; Qiusheng Guo; Zhiwen Pan; Xiaohong Xu; Xiying Shao; Xiaojia Wang
Journal:  Ann Transl Med       Date:  2021-08

5.  The activity level of follicular helper T cells in the peripheral blood of osteosarcoma patients is associated with poor prognosis.

Authors:  Jianshu Lu; Xiuqin Kang; Zhitao Wang; Gang Zhao; Baoen Jiang
Journal:  Bioengineered       Date:  2022-02       Impact factor: 3.269

Review 6.  Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies.

Authors:  Kamira Maharaj; Angimar Uriepero; Eva Sahakian; Javier Pinilla-Ibarz
Journal:  Front Immunol       Date:  2022-08-01       Impact factor: 8.786

Review 7.  Stromal and Immune Cell Dynamics in Tumor Associated Tertiary Lymphoid Structures and Anti-Tumor Immune Responses.

Authors:  Alessandra Rossi; Beatrice Belmonte; Silvia Carnevale; Antonietta Liotti; Veronica De Rosa; Sebastien Jaillon; Silvia Piconese; Claudio Tripodo
Journal:  Front Cell Dev Biol       Date:  2022-07-08

Review 8.  CXCL13 in Cancer and Other Diseases: Biological Functions, Clinical Significance, and Therapeutic Opportunities.

Authors:  San-Hui Gao; Sheng-Zhi Liu; Gui-Zhen Wang; Guang-Biao Zhou
Journal:  Life (Basel)       Date:  2021-11-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.